CN1207296C - 抑制法尼基转移酶的1,2－增环喹啉对映体 - Google Patents

抑制法尼基转移酶的1,2－增环喹啉对映体 Download PDF

Info

Publication number
CN1207296C
CN1207296C CNB018113788A CN01811378A CN1207296C CN 1207296 C CN1207296 C CN 1207296C CN B018113788 A CNB018113788 A CN B018113788A CN 01811378 A CN01811378 A CN 01811378A CN 1207296 C CN1207296 C CN 1207296C
Authority
CN
China
Prior art keywords
acid
chlorophenyl
pharmaceutically acceptable
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018113788A
Other languages
English (en)
Chinese (zh)
Other versions
CN1437601A (zh
Inventor
M·G·韦内
P·R·安日博
D·W·恩德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1437601A publication Critical patent/CN1437601A/zh
Application granted granted Critical
Publication of CN1207296C publication Critical patent/CN1207296C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB018113788A 2000-06-22 2001-06-13 抑制法尼基转移酶的1,2－增环喹啉对映体 Expired - Lifetime CN1207296C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
EP00202181.4 2000-06-22

Publications (2)

Publication Number Publication Date
CN1437601A CN1437601A (zh) 2003-08-20
CN1207296C true CN1207296C (zh) 2005-06-22

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018113788A Expired - Lifetime CN1207296C (zh) 2000-06-22 2001-06-13 抑制法尼基转移酶的1,2－增环喹啉对映体

Country Status (33)

Country Link
US (3) US20030114471A1 (enExample)
EP (1) EP1296984B1 (enExample)
JP (1) JP4919575B2 (enExample)
KR (2) KR100846370B1 (enExample)
CN (1) CN1207296C (enExample)
AR (1) AR030704A1 (enExample)
AT (1) ATE294804T1 (enExample)
AU (3) AU6396201A (enExample)
BG (1) BG65894B1 (enExample)
BR (1) BRPI0111743B8 (enExample)
CA (1) CA2410232C (enExample)
CZ (1) CZ295278B6 (enExample)
DE (1) DE60110592T2 (enExample)
EA (1) EA005065B1 (enExample)
EE (1) EE04966B1 (enExample)
EG (1) EG24180A (enExample)
ES (1) ES2241830T3 (enExample)
HR (1) HRP20020989B1 (enExample)
HU (1) HU229095B1 (enExample)
IL (2) IL153560A0 (enExample)
IS (1) IS2596B (enExample)
JO (1) JO2361B1 (enExample)
MX (1) MXPA02012845A (enExample)
MY (1) MY127734A (enExample)
NO (1) NO324494B1 (enExample)
NZ (1) NZ522481A (enExample)
PA (1) PA8519501A1 (enExample)
PL (1) PL209521B1 (enExample)
SA (1) SA01220349B1 (enExample)
SK (1) SK285699B6 (enExample)
UA (1) UA73572C2 (enExample)
WO (1) WO2001098302A1 (enExample)
ZA (1) ZA200210305B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EP3226973A4 (en) * 2014-12-04 2018-05-30 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10835496B2 (en) 2015-04-21 2020-11-17 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
EA201890512A1 (ru) 2015-08-17 2018-09-28 Кура Онколоджи, Инк. Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
RS61745B1 (sr) 2016-11-03 2021-05-31 Kura Oncology Inc Inhibitori farneziltransferaze za upotrebu u tretiranju kancera

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EE03484B1 (et) * 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
BR9809398A (pt) * 1997-04-25 2000-06-13 Janssen Pharmaceutica Nv Quinazolinonas que inibem a farnesil transferase
ATE222104T1 (de) 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
US6545020B1 (en) * 1998-07-06 2003-04-08 Janssen Pharmaceutica, N.V. Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
TR200101343T2 (tr) * 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
ATE289602T1 (de) * 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
BR9916827A (pt) * 1998-12-23 2001-10-16 Janssen Pharmaceutica Nv Derivados de quinolina 1,2-anelados
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
KR20010102073A (ko) * 1999-02-11 2001-11-15 실버스타인 아써 에이. 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6838467B2 (en) * 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体

Also Published As

Publication number Publication date
JP2004501153A (ja) 2004-01-15
MY127734A (en) 2006-12-29
HU229095B1 (en) 2013-07-29
US8318753B2 (en) 2012-11-27
SK502003A3 (en) 2003-05-02
WO2001098302A1 (en) 2001-12-27
US20080114009A1 (en) 2008-05-15
CA2410232C (en) 2008-10-07
PL209521B1 (pl) 2011-09-30
DE60110592T2 (de) 2006-01-19
BG65894B1 (bg) 2010-04-30
KR100831940B1 (ko) 2008-05-23
HUP0300872A3 (en) 2004-11-29
HRP20020989A2 (en) 2005-02-28
AR030704A1 (es) 2003-09-03
UA73572C2 (en) 2005-08-15
EA005065B1 (ru) 2004-10-28
AU2001263962B2 (en) 2006-07-20
EE04966B1 (et) 2008-02-15
IS6590A (is) 2002-10-25
SA01220349B1 (ar) 2007-01-23
PL358918A1 (en) 2004-08-23
AU2006220405A1 (en) 2006-10-12
JP4919575B2 (ja) 2012-04-18
NO324494B1 (no) 2007-10-29
EP1296984A1 (en) 2003-04-02
BR0111743A (pt) 2003-07-08
IL153560A0 (en) 2003-07-06
US20030114471A1 (en) 2003-06-19
EG24180A (en) 2008-09-28
US8329714B2 (en) 2012-12-11
ATE294804T1 (de) 2005-05-15
CA2410232A1 (en) 2001-12-27
AU2006220405B2 (en) 2009-05-21
PA8519501A1 (es) 2002-08-29
CZ295278B6 (cs) 2005-06-15
JO2361B1 (en) 2006-12-12
CZ2003114A3 (cs) 2003-05-14
DE60110592D1 (de) 2005-06-09
CN1437601A (zh) 2003-08-20
BRPI0111743B8 (pt) 2021-05-25
BG107310A (bg) 2003-07-31
HK1058363A1 (en) 2004-05-14
NO20026032D0 (no) 2002-12-16
BRPI0111743B1 (pt) 2019-03-26
EE200200695A (et) 2004-06-15
ES2241830T3 (es) 2005-11-01
AU6396201A (en) 2002-01-02
IS2596B (is) 2010-03-15
KR100846370B1 (ko) 2008-07-15
HUP0300872A2 (hu) 2003-07-28
EA200300048A1 (ru) 2003-04-24
NZ522481A (en) 2004-09-24
ZA200210305B (en) 2004-03-19
HRP20020989B1 (hr) 2011-05-31
EP1296984B1 (en) 2005-05-04
SK285699B6 (sk) 2007-06-07
US20070259902A1 (en) 2007-11-08
MXPA02012845A (es) 2003-05-15
KR20030009463A (ko) 2003-01-29
KR20070121847A (ko) 2007-12-27
NO20026032L (no) 2002-12-16
IL153560A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
TW200806664A (en) Azaindoles useful as inhibitors of janus kinases
JP4974439B2 (ja) ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
US8329714B2 (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
TW201609743A (zh) 咪唑并嗒化合物
TWI616445B (zh) 新穎環丙苯并呋喃基吡啶并吡二酮類
JP4450628B2 (ja) ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体
AU2001263962A1 (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
JP4537710B2 (ja) ファルネシルトランスフェラーゼ阻害剤としての炭素連結トリアゾールで置換されている１，８−アネル化キノリン誘導体
HK1058363B (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
JP4384505B2 (ja) ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体
TWI298723B (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050622